Patents by Inventor Eric NEWCOMB

Eric NEWCOMB has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibitors of adenosine 5?-nucleotidase
    Patent number: 12168023
    Abstract: Compounds that modulate the conversion of AMP to adenosine by 5?-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5?-nucleotidase, ecto is also provided.
    Type: Grant
    Filed: April 8, 2024
    Date of Patent: December 17, 2024
    Assignee: Arcus Biosciences, Inc.
    Inventors: Laurent Pierre Paul Debien, Jaroslaw Kalisiak, Kenneth V. Lawson, Manmohan Reddy Leleti, Erick Allen Lindsey, Dillon Harding Miles, Eric Newcomb, Jay Patrick Powers, Brandon Reid Rosen, Ehesan Ul Sharif
  • MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF
    Publication number: 20240352057
    Abstract: Compounds that modulate the conversion of AMP to adenosine by 5?-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5?-nucleotidase, ecto is also provided.
    Type: Application
    Filed: November 21, 2023
    Publication date: October 24, 2024
    Inventors: Laurent Pierre Paul DEBIEN, Juan Carlos Jaen, Jaroslaw Kalisiak, Kenneth V. Lawson, Manmohan Reddy Leleti, Erick Allen Lindsey, Dillon Harding Miles, Eric Newcomb, Jay Patrick Powers, Brandon Reid Rosen, Ehesan Ui Sharif
  • INHIBITORS OF ADENOSINE 5'-NUCLEOTIDASE
    Publication number: 20240285665
    Abstract: Compounds that modulate the conversion of AMP to adenosine by 5?-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5?-nucleotidase, ecto is also provided.
    Type: Application
    Filed: April 8, 2024
    Publication date: August 29, 2024
    Inventors: Laurent Pierre Paul DEBIEN, Jaroslaw Kalisiak, Kenneth V. Lawson, Manmohan Reddy Leleti, Erick Allen Lindsey, Dillon Harding Miles, Eric Newcomb, Jay Patrick Powers, Brandon Reid Rosen, Ehesan UI Sharif
  • Modulators of 5?-nucleotidase, ecto and the use thereof
    Patent number: 11667662
    Abstract: Compounds that modulate the conversion of AMP to adenosine by 5?-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5?-nucleotidase, ecto is also provided.
    Type: Grant
    Filed: March 19, 2021
    Date of Patent: June 6, 2023
    Assignee: ARCUS BIOSCIENCES, INC.
    Inventors: Laurent Pierre Paul Debien, Juan Carlos Jaen, Jaroslaw Kalisiak, Kenneth V. Lawson, Manmohan Reddy Leleti, Erick Allen Lindsey, Dillon Harding Miles, Eric Newcomb, Jay Patrick Powers, Brandon Reid Rosen, Ehesan Ui Sharif
  • Inhibitors of CD73-mediated immunosuppression
    Patent number: 11267845
    Abstract: Compounds that modulate the conversion of AMP to adenosine by 5?-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5?-nucleotidase, ecto is also provided.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: March 8, 2022
    Assignee: ARCUS BIOSCIENCES, INC.
    Inventors: Jaroslaw Kalisiak, Kenneth V. Lawson, Manmohan Reddy Leleti, Erick Allen Lindsey, Dillon Harding Miles, Eric Newcomb, Jay Patrick Powers, Ehesan Ul Sharif
  • MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF
    Publication number: 20210371449
    Abstract: Compounds that modulate the conversion of AMP to adenosine by 5?-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5?-nucleotidase, ecto is also provided.
    Type: Application
    Filed: March 19, 2021
    Publication date: December 2, 2021
    Inventors: Laurent Pierre Paul DEBIEN, Juan Carlos JAEN, Jaroslaw KALISIAK, Kenneth V. LAWSON, Manmohan Reddy LELETI, Erick Allen LINDSEY, Dillon Harding MILES, Eric NEWCOMB, Jay Patrick POWERS, Brandon Reid ROSEN, Ehesan Ul SHARIF
  • Inhibitors of adenosine 5?-nucleotidase
    Patent number: 11058704
    Abstract: Compounds that modulate the conversion of AMP to adenosine by 5?-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5?-nucleotidase, ecto is also provided.
    Type: Grant
    Filed: October 2, 2017
    Date of Patent: July 13, 2021
    Assignee: ARCUS BIOSCIENCES, INC.
    Inventors: Laurent Pierre Paul Debien, Jaroslaw Kalisiak, Kenneth V. Lawson, Manmohan Reddy Leleti, Erick Allen Lindsey, Dillon Harding Miles, Eric Newcomb, Jay Patrick Powers, Brandon Reid Rosen, Ehesan Ul Sharif
  • Modulators of 5?-nucleotidase, ecto and the use thereof
    Patent number: 11001603
    Abstract: Compounds that modulate the conversion of AMP to adenosine by 5?-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5?-nucleotidase, ecto is also provided.
    Type: Grant
    Filed: September 1, 2020
    Date of Patent: May 11, 2021
    Assignee: ARCUS BIOSCIENCES, INC.
    Inventors: Laurent Pierre Paul Debien, Juan Carlos Jaen, Jaroslaw Kalisiak, Kenneth V. Lawson, Manmohan Reddy Leleti, Erick Allen Lindsey, Dillon Harding Miles, Eric Newcomb, Jay Patrick Powers, Brandon Reid Rosen, Ehesan Ul Sharif
  • Modulators of 5?-nucleotidase, ecto and the use thereof
    Patent number: 10981944
    Abstract: Compounds that modulate the conversion of AMP to adenosine by 5?-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5?-nucleotidase, ecto is also provided.
    Type: Grant
    Filed: February 12, 2019
    Date of Patent: April 20, 2021
    Assignee: ARCUS BIOSCIENCES, INC.
    Inventors: Laurent Pierre Paul Debien, Juan Carlos Jaen, Jaroslaw Kalisiak, Kenneth V. Lawson, Manmohan Reddy Leleti, Erick Allen Lindsey, Dillon Harding Miles, Eric Newcomb, Jay Patrick Powers, Brandon Reid Rosen, Ehesan Ul Sharif
  • MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF
    Publication number: 20210002322
    Abstract: Compounds that modulate the conversion of AMP to adenosine by 5?-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5?-nucleotidase, ecto is also provided.
    Type: Application
    Filed: September 1, 2020
    Publication date: January 7, 2021
    Inventors: Laurent Pierre Paul DEBIEN, Juan Carlos JAEN, Jaroslaw KALISIAK, Kenneth V. LAWSON, Manmohan Reddy LELETI, Erick Allen LINDSEY, Dillon Harding MILES, Eric NEWCOMB, Jay Patrick POWERS, Brandon Reid ROSEN, Ehesan Ul SHARIF
  • INHIBITORS OF ADENOSINE 5'-NUCLEOTIDASE
    Publication number: 20200222441
    Abstract: Compounds that modulate the conversion of AMP to adenosine by 5?-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5?-nucleotidase, ecto is also provided.
    Type: Application
    Filed: October 2, 2017
    Publication date: July 16, 2020
    Inventors: Laurent Pierre Paul DEBIEN, Jaroslaw KALISIAK, Kenneth V. LAWSON, Manmohan Reddy LELETI, Erick Allen LINDSEY, Dillon Harding MILES, Eric NEWCOMB, Jay Patrick POWERS, Brandon Reid ROSEN, Ehesan Ul SHARIF
  • INHIBITORS OF CD73-MEDIATED IMMUNOSUPPRESSION
    Publication number: 20200062797
    Abstract: Compounds that modulate the conversion of AMP to adenosine by 5?-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5?-nucleotidase, ecto is also provided.
    Type: Application
    Filed: November 17, 2017
    Publication date: February 27, 2020
    Inventors: Jaroslaw KALISIAK, Kenneth V. LAWSON, Manmohan Reddy LELETI, Erick Allen LINDSEY, Dillon Harding MILES, Eric NEWCOMB, Jay Patrick POWERS, Ehesan Ul SHARIF
  • MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF
    Publication number: 20190309010
    Abstract: Compounds that modulate the conversion of AMP to adenosine by 5?-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5?-nucleotidase, ecto is also provided.
    Type: Application
    Filed: February 12, 2019
    Publication date: October 10, 2019
    Inventors: Laurent Pierre Paul DEBIEN, Juan Carlos Jaen, Jaroslaw Kalisiak, Kenneth V. Lawson, Manmohan Reddy Leleti, Erick Allen Lindsey, Dillon Harding Miles, Eric Newcomb, Jay Patrick Powers, Brandon Reid Rosen, Ehesan Ul Sharif
  • Modulators of 5?-nucleotidase, ecto and the use thereof
    Patent number: 10239912
    Abstract: Compounds that modulate the conversion of AMP to adenosine by 5?-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5?-nucleotidase, ecto is also provided.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: March 26, 2019
    Assignee: ARCUS BIOSCIENCES, INC.
    Inventors: Laurent Pierre Paul Debien, Juan Carlos Jaen, Jaroslaw Kalisiak, Kenneth V. Lawson, Manmohan Reddy Leleti, Erick Allen Lindsey, Dillon Harding Miles, Eric Newcomb, Jay Patrick Powers, Brandon Reid Rosen, Ehesan Ul Sharif
  • MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF
    Publication number: 20170267710
    Abstract: Compounds that modulate the conversion of AMP to adenosine by 5?-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5?-nucleotidase, ecto is also provided.
    Type: Application
    Filed: January 6, 2017
    Publication date: September 21, 2017
    Inventors: Laurent Pierre Paul DEBIEN, Juan Carlos JAEN, Jaroslaw KALISIAK, Kenneth V. LAWSON, Manmohan Reddy LELETI, Erick Allen LINDSEY, Dillon Harding MILES, Eric NEWCOMB, Jay Patrick POWERS, Brandon Reid Rosen, Ehesan Ul Sharif